Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19097949 | 1.00 | MAPT (0.32) | MAPTALDH1A1 | |
| Cadaverine Tartrate SCHEMBL30846801 | 0.84 | TSHR (0.32) | — | |
| Cadaverine Tartrate SCHEMBL20548905 | 0.84 | TSHR (0.32) | — | |
| SCHEMBL6266247 | 0.67 | MAPT (0.32) | MAPT | |
| SCHEMBL31046650 | 0.65 | MAPT (0.38) | MAPTALDH1A1 | |
| SCHEMBL6685775 | 0.65 | ALDH1A1 (0.37) | MAPTALDH1A1 | |
| SCHEMBL8450841 | 0.65 | ALDH1A1 (0.37) | MAPTALDH1A1 | |
| SCHEMBL5560867 | 0.65 | ALDH1A1 (0.37) | MAPTALDH1A1 | |
| SCHEMBL785503 | 0.65 | ALDH1A1 (0.37) | MAPTALDH1A1 | |
| SCHEMBL5560865 | 0.65 | ALDH1A1 (0.37) | MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215003-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB | GRANULES INDIA LIMITED (IN) | 2025-07-03 | — | — | US | disclosed |
| CN-120058609-A | Medicinal salt of (R) -5-cyclopentyl pyrazolidine-3-ketone, preparation method and application thereof | 四川科伦药物研究院有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-119032095-A | Improved process for preparing ruxolitinib | 印度颗粒有限公司 | 2024-11-26 | — | — | CN | disclosed |
| EP-4463460-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB | Granules India Limited (IN) | 2024-11-20 | — | — | EP | disclosed |
| WO-2024042448-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB | GRANULES INDIA LIMITED (IN) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024042448-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB | GRANULES INDIA LIMITED (IN) | 2024-02-29 | — | — | WO | disclosed |
| CN-111875607-B | Preparation method of chiral pyrrolopyrimidine compound | 正大天晴药业集团股份有限公司 | 2021-12-03 | — | — | CN | disclosed |
| CN-111763209-B | Synthesis process of luccotinib | 正大天晴药业集团股份有限公司 | 2021-12-03 | — | — | CN | disclosed |
| EP-3473626-B1 | PYRROLOPYRIMIDINE CRYSTAL FOR PREPARING JAK INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2021-08-04 | — | — | EP | disclosed |
| EP-3473626-B1 | PYRROLOPYRIMIDINE CRYSTAL FOR PREPARING JAK INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2021-08-04 | — | — | EP | disclosed |
| EP-3473625-A1 | PREPARATION METHOD FOR CHIRAL PYRROLOPYRIMIDINE COMPOUND | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-04-24 | — | — | EP | disclosed |
| EP-3473626-A1 | PYRROLOPYRIMIDINE CRYSTAL FOR PREPARING JAK INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-04-24 | — | — | EP | disclosed |
| EP-3473626-A1 | PYRROLOPYRIMIDINE CRYSTAL FOR PREPARING JAK INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-04-24 | — | — | EP | disclosed |
| EP-3473625-A1 | PREPARATION METHOD FOR CHIRAL PYRROLOPYRIMIDINE COMPOUND | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-04-24 | — | — | EP | disclosed |
| US-20190023712-A1 | SYNTHESIS PROCESS OF RUXOLITINIB | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-01-24 | — | — | US | disclosed |
| US-20190023712-A1 | SYNTHESIS PROCESS OF RUXOLITINIB | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-01-24 | — | — | US | disclosed |
| EP-3398952-A1 | SYNTHESIS PROCESS OF RUXOLITINIB | Chai Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2018-11-07 | — | — | EP | disclosed |
| WO-2017215627-A1 | PREPARATION METHOD FOR CHIRAL PYRROLOPYRIMIDINE COMPOUND | 正大天晴药业集团股份有限公司 | 2017-12-21 | — | — | WO | disclosed |
| WO-2017114461-A1 | SYNTHESIS PROCESS OF RUXOLITINIB | 正大天晴药业集团股份有限公司 | 2017-07-06 | — | — | WO | disclosed |
| US-20120022058-A1 | 4,5-DIHYDRO-1H-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES | PFIZER INC. | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215003-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB | JAK1, JAK3, JAK2 | MAPT 3976/4885ALDH1A1 2994/4885 |
| US-20190023712-A1 | SYNTHESIS PROCESS OF RUXOLITINIB | JAK3, JAK1, JAK2 | MAPT 4661/4885ALDH1A1 1889/4885 |
| US-20120022058-A1 | 4,5-DIHYDRO-1H-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES | NR3C2, REN, AGTR1 | MAPT 3989/4885ALDH1A1 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.